NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.13 -2.80 (-3.42%) GOLD FUTURES
2,330.20 +27.30 (+1.19%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,165.89 -1,874.25 (-3.90%)
Oxford BioDynamics Plc (OBD.L)
| Previous close | 8.54 |
| Open | 8.80 |
| Bid | 8.30 x 0 |
| Ask | 8.80 x 0 |
| Day's range | 8.02 - 8.80 |
| 52-week range | 7.80 - 52.00 |
| Volume | |
| Avg. volume | 527,653 |
| Market cap | 25.884M |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.07 |
| Earnings date | 28 May 2024 - 03 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Is Oxford BioDynamics (LON:OBD) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Business WireBupa UK to cover EpiSwitch® CiRT for customers with cancer
OXFORD, England, October 18, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT (Checkpoint inhibitor Response Test).
Business WireOxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test
OXFORD, England, October 03, 2023--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform, confirms the assignment and publication of a Proprietary Laboratory Analysis Code (PLA Code) by the American Medical Association’s CPT (Current Procedural Terminology) Editorial Board (https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes).
